E-Therapeutics: Rewards For Keeping The Faith
Edison | Dec 12, 2018 08:40AM ET
E-Therapeutics Plc (LON:ETXP) has announced a long-awaited research collaboration with Novo Nordisk (CO:NOVOb) (Novo) on early target discovery in diabetes. This is the first commercial collaboration in ETX’s history and will last for at least a year. The financial terms of the transaction were not disclosed but the deal should be recognised for its validation of ETX’s disease-aware network-driven drug discovery (NDD) platform. This is expected to be the first in an expected series of deals on the NDD platform and the assets generated from it.
The long-awaited first commercial deal
In a continued flurry of good news, ETX has announced a collaboration with Novo – the world leader in metabolic diseases – in type II diabetes (T2D). The collaboration will run for a year in the first instance, during which ETX will be reimbursed for its work. At the end of the period, Novo has the option to license the relevant intellectual property. T2D is a large and commercially significant market where successful new products with novel modes of action can command price premiums. ETX’s share price dropped c 5% on the announcement. The financial terms were not disclosed but we expect ETX to have entered into a transaction with Novo with at least a ‘cost plus’ structure to the first phase and the option for a license exists after a year. The extent of that ‘plus’ will likely be made clearer at ETX’s FY19 results in March. This development highlights the NDD platform as a springboard for further transactions in other therapy areas.
To read the entire report Please click on the pdf File Below..
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.